enGene Therapeutics (ENGN) Other Operating Expenses (2024 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other Operating Expenses of -$4.1 million for Q2 2026, down 64.1% year-over-year from -$11.4 million in Q2 2025, and down 8.0% quarter-over-quarter from -$3.8 million in Q1 2026.
enGene Therapeutics (ENGN) Other Operating Expenses (2024 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Operating Expenses for 3 consecutive years, with -$4.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses fell 64.1% year-over-year to -$4.1 million; the TTM figure through Apr 2026 stood at -$7.9 million (up 91.17% YoY), while the FY2025 annual figure was -$11.5 million, up 82.9% from the prior year.
- Other Operating Expenses slipped to -$4.1 million in Q2 2026 per ENGN's latest filing, from -$3.8 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$2.5 million in Q2 2025 and bottomed at -$55.1 million in Q4 2024.
- Historically, Other Operating Expenses has averaged -$19.4 million across 3 years, with a median of -$4.1 million in 2026.
- On a YoY basis, Other Operating Expenses climbed as much as 88.03% in 2026 and fell as far as 64.1% in 2026.
- enGene Therapeutics' Other Operating Expenses stood at -$55.1 million in 2024, then soared by 95.48% to -$2.5 million in 2025, then slumped by 64.1% to -$4.1 million in 2026.
- Business Quant data shows ENGN's Other Operating Expenses at -$4.1 million in Q2 2026, -$3.8 million in Q1 2026, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -4.09 Mn |
| Jan 31, 2026 | -3.79 Mn |
| Apr 30, 2025 | -2.49 Mn |
| Jan 31, 2025 | -31.64 Mn |
| Oct 31, 2024 | -55.14 Mn |